I do not see jack in anything this company is doing. Buy CUR....you got a chance, small but at least a POSSIBILTY.
For every per cent the NAS drops, NWBO will drop 5.5%.
It failed in UC and we still do not know jack about any MOA in the trial. BJ does not want ya to know that!
Sort of like the Furgerson PD in breaking news to Investors. To heck with them all.....crooks.
They did, but it stated that the safety analysis was complete and the efficacy study was ongoing. Der Feurerstein is a dunce. And Cramer is telling his followers to hang on their worthless Argentina Bonds......He really blew that one.
No time to back out. The only thing that will save you folks is a 1/10 R/S split with a draw on Institutional money. It's the only way out. Get the share count below 100M.
VALENCIA, Calif., November 05, 2007 /PRNewswire-FirstCall/ -- MannKind Corporation today announced results from a Phase 1a clinical evaluation of MKC253, a formulation of GLP-1 (glucagon-like peptide) on Technosphere particles that is delivered using the Company's proprietary inhaler. The study was designed as an open-label, dose escalation, controlled safety and tolerability trial, involving 26 healthy, adult, male subjects. Each subject was assigned to one of five dose levels of MKC253 inhalation powder: 0.05 mg, 0.45 mg, 0.75 mg, 1.05 mg or 1.5 mg.
The primary objective of the trial was to evaluate the tolerability of ascending doses of the investigational product as determined by the incidence and severity of reported adverse events. Secondary endpoints included pharmacokinetic parameters of plasma GLP-1 and pharmacodynamic parameters of plasma insulin and glucose.
GLP-1 plasma concentrations peaked very quickly, with a mean Tmax occurring less than 3 minutes after inhalation. In the group that received 1.5 mg of MKC253, the mean Cmax of total GLP-1 was 507 pmol/L, with active GLP-1 reaching a Cmax of 310 pmol/L. At all dose levels, MKC253 was well tolerated. Even in subjects that achieved plasma GLP-1 concentrations in excess of 100 pmol/L, the nausea and vomiting characteristically associated with such levels was not observed.
In these healthy subjects, GLP-1-induced insulin release occurred within 6 minutes of inhalation of MKC253. The insulin response was dose-dependent. The release of insulin from the pancreas was confirmed by corresponding significant increases in the levels of C-peptide. In subjects that received 1.5 mg of MKC253, blood glucose concentrations were observed to decrease for a period of approximately 20 minutes after inhalation. All subjects were fasted prior to the administration of MKC253.
A greater proportion of the GLP-1 inhaled as MKC253 remained intact during the period following administration than has been described in the li
Not only that, but this time, a Dash for Cash will be at your expense. They have no money.
I believe the Street as I pointed out yesterday.
BETHESDA, Md. (TheStreet) -- I long believed Northwest Biotherapeutics (NWBO_) buried the interim efficacy analysis of its DC-Vax brain tumor clinical study in a deep hole, never to be seen again. But these things have a way of rising to surface.
It's been nine months since Northwest Bio initiated an interim efficacy look at the DC-Vax phase III study. The company has stubbornly refused to disclose those results. Monday, I believe we found out why. It seems obvious that DC-Vax came up futile in the interim efficacy analysis of the phase III study data conducted in December 2013, leaving almost no chance the experimental cancer vaccine would delay tumor progression or prolong survival.
Absent any hope of rescuing DC-Vax from failure with the brain tumor study designed as is, Northwest Bio announced a radical -- and seemingly desperate -- re-working of the study. Monday's press release said the DC-Vax study changes were made following a "9-month process of regulatory submissions and reviews by regulators in the US, UK and Germany..." Nine months? That means Northwest Bio started the process last December, which is also when the interim efficacy analysis of the study was conducted. What a coincidence! In classic spin mode, Northwest describes the DC-Vax study changes as "enhancements" which will improve the odds of success.
My guess is that the scope of the trial has failed, but it is proceeding to hook a distribution which you can your hat on and make valid statistical inferences. Really.................
that I would surmise the trial be further corrected or enrollment amended, which is probably what has happened.
Thumbs Down??? Truth is unbearable? Praying and pumping for a pop will never do it. A lot needs to be done...........and it'll cost more than 39M.
It should be down in AFT HRS trading somewhat. I see dead money here for the time being, even as PFE irons out any potential efficacy.
Dr. Robert J. Zimmerman, S.D. serves as Board of Advisor of Amarantus BioScience, Inc. Dr. Zimmerman served as the Chief Development Officer at Jumpkicks, Inc.., and Amarantus Therapeutics, Inc. Dr. Zimmerman served as President, Chief Operating Officer and Director at Signature Bioscience, Inc. Dr. Zimmerman joined Amarantus with over 25 years of management and drug development experience in both public and privately held companies with small molecules and protein drugs. During his career, he has led numerous development teams from discovery to marketing and has a successful product development record, contributing to the market approval of several drugs and the filing of multiple investigational new drug applications. He held management positions at Signature BioScience, Inc. Dr. Zimmerman served as the Vice President of Biotechnology Research at Bayer Corporation where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. Dr. Zimmerman received a doctorate of science and a Master's of Science in Physiology and Radiobiology from the Harvard School of Public Health. He also received a Master's of science in Physiology from Ohio State University and earned a B.S. from Denison University.
Dr. Lawrence M. Schwartz, Ph.D, served as Director of the Center of Excellence in Apoptosis Research ('CEAR') and Founding Director of the Pioneer Valley Life Sciences Institute ('PVLSI') in Springfield, Mass. Dr. Schwartz serves as a Professor of Department of Biology at University of Massachusetts Amherst. His laboratory examines the molecular mechanisms that mediate cell death during normal development and in pathology. Dr. Schwartz serves as a Member of the Scientific Advisory Board at Boston Biomedical Research Institute, Inc., Jumpkicks, Inc., and Amarantus BioSciences, Inc. (alternate name, Amarantus Therapeutics, Inc.).